“Catalent Unveils Strategic Evolution: New Board Appointments, Transformational Initiatives, and a Vision for Long-Term Value”
SOMERSET, N.J.–(BUSINESS WIRE)– The stage is set for transformation as Catalent, Inc. (NYSE: CTLT), a global pioneer in shaping biopharmaceutical treatments, announces a constellation of strategic moves that signal its unwavering commitment to robust governance and the relentless pursuit of shareholder value. In a grand unveiling, Catalent’s narrative unfolds with the resonance of change and innovation.
In a masterful twist, the Board’s Nominating and Corporate Governance Committee unveils a quartet of independent directors, poised to steer Catalent towards a future brimming with potential. With the addition of Steven Barg, Frank D’Amelio, Stephanie Okey, and Michelle Ryan, the company’s Board of Directors takes on fresh vigor. This infusion of fresh perspectives fortifies the team, ensuring that 13 out of 16 directors are independent under Catalent’s rigorous director independence standards.
John Greisch, a stalwart in the healthcare landscape, takes on a commanding role as Executive Chair of the Board. His strategic leadership will extend to the new Strategic and Operational Review Committee, a beacon of promise that sets out to reshape the very fabric of Catalent’s business, strategy, and operations. Greisch’s track record as a catalyst for operational excellence and shareholder value enhancement adds a layer of excitement to this strategic endeavor.
This tale of transformation takes shape against the backdrop of a new era. Catalent’s Strategic and Operational Review Committee, chaired by Greisch, comprises a stellar cast including Steven Barg, Michelle Ryan, Gregory T. Lucier, and Jack Stahl. This assembly of luminaries is tasked with shaping recommendations that will steer Catalent’s course, propelling it towards sustained value creation.
And in this narrative of change, collaboration unfurls as Elliott Investment Management L.P., a formidable presence among Catalent’s investors, enters the stage. A Cooperation Agreement is inked, ushering in standstill agreements, voting provisions, and confidentiality commitments that underscore Catalent’s commitment to its shareholders.
The unveiling of these strategic moves is met with enthusiasm from all corners. The spotlight shines on the new directors, heralding their expertise and diverse skills. John Greisch, as the torchbearer of transformation, speaks of the Board’s unwavering confidence in Catalent’s potential for value creation.
In harmony, Alessandro Maselli, President and Chief Executive Officer, emphasizes Catalent’s relentless pursuit of operational excellence, profitability, and value creation. These actions, a harmonious blend of strategy and purpose, herald Catalent’s path towards growth and prosperity.
Marc Steinberg, Senior Portfolio Manager at Elliott, lends his voice to the symphony of change. He heralds the strategic actions as catalysts for Catalent’s realization of its full potential. The transformational steps announced today echo the chorus of change, ensuring Catalent’s ascendancy towards its zenith.
As the curtain falls on this transformative unveiling, Catalent’s future glimmers with potential. The company’s journey, a symphony of innovation and progress, unfurls with promise and a vision to reshape the landscape of biopharmaceutical innovation.
Citi takes on the role of financial advisor, while Skadden, Arps, Slate, Meagher & Flom LLP and Jones Day lend their legal expertise, orchestrating the strategic moves that promise to reshape Catalent’s trajectory.
In the grand symphony of corporate evolution, Catalent, Inc. (NYSE: CTLT) orchestrates a crescendo of transformation with the addition of four stellar independent directors. Each luminary carries a tapestry of experience that promises to weave a new narrative of innovation and growth for Catalent.
Meet Steven Barg, a maestro of investment banking, whose 30-year journey has traversed the halls of power at Goldman Sachs. His pioneering role in establishing and leading Goldman Sachs’ Global Activism and Shareholder Advisory practice radiates his commitment to strategic prowess.
Frank D’Amelio, the former CFO and EVP of Global Supply at Pfizer Inc., enters the stage with a distinguished repertoire. His orchestration of corporate finance, mergers, and global supply operations at Pfizer resonates with precision and finesse.
Stephanie Okey, the former Senior VP at Genzyme, brings a melody of rare disease therapeutics to Catalent’s symphony. Her journey from field sales to executive management showcases her aptitude for innovation and launch strategies.
Michelle Ryan, the former Treasurer of Johnson & Johnson, shines as a luminary in financial leadership. With almost three decades at Johnson & Johnson, her role in financial oversight and insights for M&A activities enriches Catalent’s strategic landscape.
These directors, each a virtuoso in their own right, will harmonize their expertise with Catalent’s vision. Together, they hold the promise of reshaping the company’s journey, charting a course towards excellence and innovation.
As the curtain rises on this new chapter, Catalent stands poised for a symphony of transformation. The blend of experience, innovation, and leadership sets the stage for a performance that promises to resonate across industries and beyond.
Catalent, Inc. (NYSE: CTLT) is a global leader in pharmaceutical and healthcare solutions. With expertise in product development, manufacturing, and supply, Catalent supports partners in delivering personalized medicines, consumer health products, and blockbuster drugs. It operates across 50+ sites, producing 80 billion doses of 8,000 products yearly. Headquartered in New Jersey, Catalent’s 18,000-strong workforce includes 3,000 scientists. Its 2022 revenue was nearly $5 billion.
Step into the future with Catalent, Inc.! This press release is like a crystal ball, revealing exciting glimpses of what’s ahead. Buckle up as we dive into the world of possibilities and potential.
Hold onto your hats, because we’re about to unveil forward-looking statements that go beyond the ordinary. Picture this: a canvas of innovation and progress, where history takes a backseat and the spotlight shines on what’s to come. From operational prowess to profitability, we’re setting the stage for a journey that’s bound to keep you on the edge of your seat.
But here’s the twist – these statements aren’t promises etched in stone. They’re a dance between the known and the unknown, guided by a symphony of risks, uncertainties, and those game-changing factors that can flip the script. It’s a tale of bold actions, unexpected twists, and the magic that happens when preparation meets opportunity.
Explore the depths of this narrative, where activist stockholders hold a subplot of intrigue, and the “Risk Factors” section reads like a suspenseful thriller. Our Annual Report on Form 10-K for the year ended June 30, 2022 (with some spicy amendments), the Quarterly Report on Form 10-Q for the dazzling three and nine months ending March 31, 2023 – it’s all part of the saga.
But wait, there’s more! Imagine a cast of characters, including the ever-watchful Securities and Exchange Commission, shaping the plot’s twists and turns. Every word in this press release is a brushstroke on the canvas of time, capturing the essence of this moment. Yet, don’t expect the story to end here. It’s a narrative that evolves, fueled by fresh information, future events, and the irresistible pull of destiny.
So, whether you’re a stakeholder, an enthusiast, or just someone with a penchant for the extraordinary, dive into these words that echo like a promise – a promise to keep you intrigued, engaged, and eagerly awaiting what’s next.
Important Additional Information and Where to Find It
Get ready to be in the know! Catalent’s got a blockbuster announcement coming your way. We’re about to send you a package of proxy materials that’s like a backstage pass to the show of the year – Catalent’s 2023 annual meeting of shareholders.
Think of it as a treasure map to our strategy vault. But before the big event, we’re spilling the beans with our “Proxy Statement.” This isn’t your average paperwork – it’s a peek into our game plan, loaded with insights and surprises.
Hold tight, shareholders! This isn’t just a suggestion; it’s a must. Every sentence, every tidbit counts. From plot twists in amendments to enriching supplements, it’s all there.
So, mark your calendar and keep an eye out. The Proxy Statement isn’t just info; it’s your VIP ticket to join the Catalent story. And trust us, you won’t want to miss this!
Certain Information Regarding Participants
Picture this: a cast of characters, each with a stake in the grand performance that is Catalent’s 2023 Annual Meeting. They’re not just names on paper; they’re the directors, the visionaries, the heartbeat of Catalent’s story.
Hold onto your curiosity, because behind the scenes, something intriguing is happening. It’s not just about numbers; it’s about who’s in the spotlight. You might be wondering – who are these key players, these potential participants that give this narrative its depth?
Get ready for a revelation that’s worth its weight in gold. These participants, though none of them possess more than a 1% share, are woven into the fabric of Catalent’s journey. Their interests, both direct and indirect, are as varied as the roles they play.
But wait, there’s more! If you’re eager for the whole backstory, it’s all in the Proxy Statement – that treasure trove of insights you won’t want to miss. It’s a glimpse into the world of holdings and interests, where everything comes to light.
And remember that 2022 Proxy Statement? It’s like a prologue to this chapter. You’ll find the groundwork there, but don’t forget – this story is still evolving. From Statements of Change in Ownership on Forms 3 and 4 filed with the SEC to the transformation of identities, it’s all part of the intrigue.
So, if you’re ready for the grand reveal of who’s who and what’s what, keep your eyes on the upcoming show. The stage is set, the characters are waiting, and the plot is about to thicken. This is Catalent’s story, and you’re invited to be part of it.